Newsbenzinga
Kazia Therapeutics Announces Sovargen Doses First Participant In Phase 1b/2a Clinical Study Of Paxalisib To Treat Epilepsies
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…